検索結果

发表论文 | 研究与开发 | 千寿制药株式会社

1-11, 2026 Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease Tomoyuki Wada1, Kazunori Omatsu1, Stephen C. P...

学会发表 | 研究与开发 | 千寿制药株式会社

5月３日～2026年5月7日 開催地：Denver, Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatrep, on the inflammatory response in dendritic cells Tsukasa Yagi, Mari Isomi, Ats...

nding under the program Cyclic Innovation for Clinical Empowerment (CiCLE) established by the Japan Agency for Medical Research and Development (AMED). (1) Hayreh SS, and Zimmerman MB. Central retinal...

d by ocular surface disorder” *. Recently, the number of DED patients has been increasing due to an aging population, the long-term use of contact lenses, and the widespread use of Visual Display Term...

产品开发方针 | 研究与开发 | 千寿制药株式会社

f world population. 2024.  #4: 横井则彦，加藤弘明：干眼症诊疗范式的变化 眼表面的分层诊断和分层治疗.京府医大期刊，2013 122(8):549-57  #5: Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, et al. RNA-Seq-based transcriptome analy...